
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Ovarian Cancer
Case: A 58-Year-Old Female With Progressive Ovarian Cancer
H & P
Imaging
Biopsy and Labs
Treatment
Follow-up






